Autologous Matrix-induced Chondrogenesis Market

• Increasing knee joint injuries are driving the market growth

Several factors are contributing to the significant expansion of the knee cartilage segment in the analyzed market, including an increase in injuries, a rise in less invasive treatments, and a rise in knee replacement surgeries. Additionally, autologous knee replacement and surgery Studies on the benefits of matrix-induced chondrogenesis (AMIC) are abundant. Nearly one million tons of the stuff were purchased in the United States in 2021, according to the American Academy of Orthopedic Association (AAOS) 2021 report. This role is expected to grow to 3.5 million per year by 2030.

Additionally, studies on the remains of Log's plants and autos implanted in surgery-diversion chondrogen testing (IMASTATIC) are abundant. According to a November 2022 ScienceDirect article, an acceptable short—and medium-term clinical outcome was obtained, for example, for the repair of chondral lesions in the knee when AMIC was used in conjunction with a hyaluronic acid scaffold. The surgical procedure enhanced sporting activities, functionality, and symptoms, and the surveyed patients expressed high levels of satisfaction with it.

Furthermore, because of sports injuries, knee surgeries are becoming more popular, and AMIC is expected to drive market expansion. In 2021, the National Safety Council (NSC) reported that injuries resulting from exercise equipment accounted for over 409,000 injuries, the highest number of any sport or leisure activity. The AMIC technique is widely utilized in knee replacements and procedures that occur during sports and leisure activities because of its promising nature as a cartilage resurfacing process.

Biomaterials and surgical techniques for AMIC therapies have improved as a result of advancements in tissue engineering and regenerative medicine. This has expedited the uptake of AMIC therapy by improving its outcomes and success rates. AMIC cartilage repair procedures are in more demand due to the growing number of older persons and their greater participation in sports and physical activities, which also increases the occurrence of knee injuries. Additionally, favorable reimbursement guidelines and insurance coverage for AMIC surgeries have facilitated patient access to this state-of-the-art therapy option in several areas.

Positively, more advancements in the AMIC business will be fueled by ongoing R&D projects, collaborations between pharmaceutical companies and healthcare providers, and growing investments in regenerative medicine. Thus, driving the Autologous Matrix-induced Chondrogenesis market revenue.

The study provides market insights into North America, Europe, Asia-Pacific, and the Rest of the World by region. The North American Autologous Matrix-induced Chondrogenesis market will dominate this market. In this region, the incidence of bone and joint ailments has risen. For instance, the Congressional Budget Office projected in January 2023 that in the United States, the proportion of persons 25–64 to age 65 or higher will increase from roughly 34% in 2023 to 46% in 2053. People living longer are more likely to suffer from bone and joint disorders since they suffer from age-related drops in essential growth factors.

This is likely to make autologous matrix-induced chondrogenesis more common throughout the projection period.

Further, the major countries studied in the market report are the US, Canada, Germany, France, the UK, Italy, Spain, China, Japan, India, Australia, and South Korea.

Figure 2: Autologous Matrix-induced Chondrogenesis Market Share By Region 2023 (USD Billion)

Source: Secondary Research, Primary Research, Market Research Future Database and Analyst Review

Europe's Autologous Matrix-induced Chondrogenesis market accounts for the second-largest market share. AMIC. It is a minimally invasive method of correcting cartilage abnormalities, systematically reducing or eliminating pain, and stopping the aerodynamic process of the degeneration of the joint impact with the participation of leading European orthopedic surgeons. Further, the German Autologous Matrix-induced Chondrogenesis market held the largest market share, and the UK Autologous Matrix-induced Chondrogenesis market was the fastest-growing market in the European region.

The Asia-Pacific Autologous Matrix-induced Chondrogenesis Market is expected to grow at the fastest CAGR from 2024 to 2032. As the economies of many Asian countries develop, the level of investment in infrastructure and medicine is growing. The research suggests that those funds are spent on state-of-the-art medical technology and particularly regenerative medications, such as AMIC. Moreover, China’s Autologous Matrix-induced Chondrogenesis market held the largest market share, and the Indian Autologous Matrix-induced Chondrogenesis market was the fastest-growing market in the Asia-Pacific region.

The industry's leading players will keep spending a lot of money on research and development to increase their product lines, which will propel the Autologous Matrix-induced Chondrogenesis market's growth. Contractual agreements, mergers and acquisitions, increased investments, collaboration with other companies, and the production of new products are examples of significant market developments. To increase their worldwide reach, market players also take part in a variety of strategic initiatives. In order to survive and expand in a more competitive and dynamic market, the Autologous Matrix-induced Chondrogenesis industry must offer reasonably priced products and services.

One of the main strategies manufacturers use in the worldwide Autologous Matrix-induced Chondrogenesis market is local manufacturing, which expands the market sector and helps customers by lowering operating costs. The Autologous Matrix-induced Chondrogenesis industry has recently provided some of the largest medical advantages. Major players in the Autologous Matrix-induced Chondrogenesis market, including Anika Therapeutics, Inc., CartiHeal, Geistlich Group (Geistlich Pharma AG), JRI Orthopaedics, Arthro-Kinetics, B. Braun SE, Smith+Nephew, Matricel GmbH, Arthrex, Vericel, Zimmer Biomet Holdings, CONMED Corporation., and others, are making investments in R&D activities in an effort to boost market demand.

Anika Therapeutics, Inc. is a global organization that develops, produces, and markets treatment for degenerative orthopedic illnesses and severe conditions. The company provides solutions for Ophthalmology, Surgery, Skincare, and Veterinary. Among its primary products for both humans and animals are joint implants, instrumentation devices, joint replacement solutions, regenerative and orthopedic surgical therapies, bone repair therapy, enhanced wound care, and ophthalmic products. Its technology states that its products are made with hyaluronic acid (HA) in the solid form known as HYAFF. Anika maintains manufacturing and research facilities in Bedford, Massachusetts.

Geistlich Pharma AG develops, produces, and distributes pharmaceuticals (anti-infectives, vitamins) and medical equipment for regenerative medicine out of its locations in central Switzerland, Wolhusen, and Root. The Geistlich group, which has been family-owned since 1851, includes the Swiss corporation. Geistlich Biomaterials, Geistlich Surgery, and Geistlich Medical are the three business divisions that makeup Geistlich Pharma. It also has ten subsidiaries and a global distribution network. About 500 people worldwide are employed by the company. Its business subsidiary, Geistlich Biomaterials, is leading the way in regenerative dentistry globally.

The ownership structure supports the company's ongoing long-term planning and innovation in new product development. Geistlich Pharma AG continuously invests in the development of its technology and research, and it counts on its knowledgeable and competent workforce.